![]() | |
Clinical data | |
---|---|
Trade names | Ingrezza |
Other names | NBI-98854 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a617023 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | >99% |
Metabolism | Activation by hydrolysis, deactivation by CYP3A, CYP2D6 |
Metabolites | [+]-α-Dihydrotetrabenazine (active metabolite) |
Elimination half-life | 15–22 hrs |
Excretion | 60% urine, 30% faeces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.236.234 |
Chemical and physical data | |
Formula | C24H38N2O4 |
Molar mass | 418.578 g·mol−1 |
3D model (JSmol) | |
| |
|
Valbenazine, sold under the brand name Ingrezza, is a medication used to treat tardive dyskinesia.[1] It acts as a vesicular monoamine transporter 2 (VMAT2) inhibitor.[2]